Book contents
- Frontmatter
- Contents
- List of contributors
- Foreword – Alan B. Scott
- Preface
- 1 The pretherapeutic history of botulinum toxin
- 2 Botulinum toxin: history of clinical development
- 3 Pharmacology of botulinum toxin drugs
- 4 Immunological properties of botulinum toxins
- 5 Treatment of cervical dystonia
- 6 Treatment of hemifacial spasm
- 7 Treatment of blepharospasm
- 8 Treatment of oromandibular dystonia
- 9 Treatment of focal hand dystonia
- 10 Botulinum toxin applications in ophthalmology
- 11 Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes
- 12 The use of botulinum toxin in otorhinolaryngology
- 13 Spasticity
- 14 The use of botulinum toxin in spastic infantile cerebral palsy
- 15 Hyperhidrosis
- 16 Cosmetic uses of botulinum toxins
- 17 Botulinum toxin in the gastrointestinal tract
- 18 Botulinum toxin in urological disorders
- 19 Use of botulinum toxin in musculoskeletal pain and arthritis
- 20 The use of botulinum toxin in the management of headache disorders
- 21 Treatment of plantar fasciitis with botulinum toxin
- 22 Treatment of stiff-person syndrome with botulinum toxin
- 23 Botulinum toxin in tic disorders and essential hand and head tremor
- 24 Developing the next generation of botulinum toxin drugs
- Index
- References
5 - Treatment of cervical dystonia
Published online by Cambridge University Press: 28 July 2009
- Frontmatter
- Contents
- List of contributors
- Foreword – Alan B. Scott
- Preface
- 1 The pretherapeutic history of botulinum toxin
- 2 Botulinum toxin: history of clinical development
- 3 Pharmacology of botulinum toxin drugs
- 4 Immunological properties of botulinum toxins
- 5 Treatment of cervical dystonia
- 6 Treatment of hemifacial spasm
- 7 Treatment of blepharospasm
- 8 Treatment of oromandibular dystonia
- 9 Treatment of focal hand dystonia
- 10 Botulinum toxin applications in ophthalmology
- 11 Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes
- 12 The use of botulinum toxin in otorhinolaryngology
- 13 Spasticity
- 14 The use of botulinum toxin in spastic infantile cerebral palsy
- 15 Hyperhidrosis
- 16 Cosmetic uses of botulinum toxins
- 17 Botulinum toxin in the gastrointestinal tract
- 18 Botulinum toxin in urological disorders
- 19 Use of botulinum toxin in musculoskeletal pain and arthritis
- 20 The use of botulinum toxin in the management of headache disorders
- 21 Treatment of plantar fasciitis with botulinum toxin
- 22 Treatment of stiff-person syndrome with botulinum toxin
- 23 Botulinum toxin in tic disorders and essential hand and head tremor
- 24 Developing the next generation of botulinum toxin drugs
- Index
- References
Summary
Introduction
Cervical dystonia (CD), originally known as spasmodic torticollis and first described by Foltz in 1959, is a neurological syndrome characterized by abnormal head and neck posture due to tonic involuntary contractions in a set of cervical muscles (Foltz et al., 1959). Myoclonic or tremulous movements are often superimposed in CD, producing a “tremor like” appearance – especially early in the disease state. The terms CD and spasmodic torticollis are not interchangeable: CD is the preferred term when referring to idiopathic focal dystonia of the neck. Spasmodic torticollis is now considered to be one of four types of CD. Cervical dystonia is classified into four types based on the principal direction of head posture: torticollis (abnormal rotation of the head to the right or to the left in the transverse plane); laterocollis (the head tilts toward the right or left shoulder); anterocollis (the head pulls forward with neck flexion); and retrocollis (the head pulls back with the neck hyperextended).
Cervical dystonia is slightly more common in females, with a male to female ratio of 1:1.2 (Kessler et al., 1999). Onset is usually insidious, although in some patients the onset has been reported as sudden. Cervical dystonia may develop in patients of all age groups, but the peak age of onset is 41 years (Kessler et al., 1999). Idiopathic CD usually progresses in severity over the first five years until it reaches a plateau, during which time the CD remains fairly constant and becomes a lifelong condition.
- Type
- Chapter
- Information
- Manual of Botulinum Toxin Therapy , pp. 29 - 42Publisher: Cambridge University PressPrint publication year: 2009
References
- 2
- Cited by